Product Description
Mechanisms of Action: KRAS Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for PF-07934040](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: Puerto Rico, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Colorectal Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
C5421001 | P1 |
Recruiting |
Non-Small-Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer|Pancreatic Ductal Carcinoma |
2027-06-08 |